These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1140 related items for PubMed ID: 17462723

  • 1. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands.
    Kerkmeijer LG, Wielsma S, Massuger LF, Sweep FC, Thomas CM.
    Gynecol Oncol; 2007 Jul; 106(1):142-6. PubMed ID: 17462723
    [Abstract] [Full Text] [Related]

  • 2. Persistent trophoblast disease following partial molar pregnancy.
    Wielsma S, Kerkmeijer L, Bekkers R, Pyman J, Tan J, Quinn M.
    Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):119-23. PubMed ID: 16638033
    [Abstract] [Full Text] [Related]

  • 3. Guidelines following hydatidiform mole: a reappraisal.
    Kerkmeijer L, Wielsma S, Bekkers R, Pyman J, Tan J, Quinn M.
    Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):112-8. PubMed ID: 16638032
    [Abstract] [Full Text] [Related]

  • 4. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy.
    Wolfberg AJ, Feltmate C, Goldstein DP, Berkowitz RS, Lieberman E.
    Obstet Gynecol; 2004 Sep; 104(3):551-4. PubMed ID: 15339768
    [Abstract] [Full Text] [Related]

  • 5. Persistence of gestational trophoblastic disease for longer than 1 year following evacuation of hydatidiform mole.
    Elmer DB, Granai CO, Ball HG, Curry SL.
    Obstet Gynecol; 1993 May; 81(5 ( Pt 2)):888-90. PubMed ID: 7682320
    [Abstract] [Full Text] [Related]

  • 6. Pre-evacuation hCG glycoforms in uneventful complete hydatidiform mole and persistent trophoblastic disease.
    Thomas CM, Kerkmeijer LG, Ariaens HJ, van der Steen RC, Massuger LF, Sweep FC.
    Gynecol Oncol; 2010 Apr; 117(1):47-52. PubMed ID: 20116088
    [Abstract] [Full Text] [Related]

  • 7. Serum levels of macrophage colony-stimulating factor in trophoblastic disease.
    Kohorn EI, Kacinski BM, Stanley ER.
    Gynecol Oncol; 2001 Mar; 80(3):383-6. PubMed ID: 11263936
    [Abstract] [Full Text] [Related]

  • 8. Low risk of relapse after achieving undetectable HCG levels in women with partial molar pregnancy.
    Wolfberg AJ, Growdon WB, Feltmate CM, Goldstein DP, Genest DR, Chinchilla ME, Berkowitz RS, Lieberman ES.
    Obstet Gynecol; 2006 Aug; 108(2):393-6. PubMed ID: 16880311
    [Abstract] [Full Text] [Related]

  • 9. Measurement of CA-125 in trophoblastic disease.
    Kohorn EI.
    Gynecol Oncol; 2000 Jul; 78(1):39-42. PubMed ID: 10873407
    [Abstract] [Full Text] [Related]

  • 10. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.
    Braga A, Maestá I, Matos M, Elias KM, Rizzo J, Viggiano MG.
    Gynecol Oncol; 2015 Nov; 139(2):283-7. PubMed ID: 26383828
    [Abstract] [Full Text] [Related]

  • 11. Plasma human chorionic gonadotropin disappearance in hydatidiform mole: a central registry report from the Netherlands.
    Franke HR, Risse EK, Kenemans P, Houx PC, Stolk JG, Vooijs GP.
    Obstet Gynecol; 1983 Oct; 62(4):467-73. PubMed ID: 6888825
    [Abstract] [Full Text] [Related]

  • 12. Characteristics of women with recurrent molar pregnancies.
    Lorigan PC, Sharma S, Bright N, Coleman RE, Hancock BW.
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):288-92. PubMed ID: 10985882
    [Abstract] [Full Text] [Related]

  • 13. [Analysis of prophylactic chemotherapy outcome and clinical characteristics in patients of high-risk hydatidiform mole].
    Geng S, Feng FZ, Xiang Y, Wan XR, Zhou Y.
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):24-7. PubMed ID: 21429430
    [Abstract] [Full Text] [Related]

  • 14. Outcome of pregnancies occurring before completion of human chorionic gonadotropin follow-up in patients with persistent gestational trophoblastic tumor.
    Tuncer ZS, Bernstein MR, Goldstein DP, Berkowitz RS.
    Gynecol Oncol; 1999 Jun; 73(3):345-7. PubMed ID: 10366457
    [Abstract] [Full Text] [Related]

  • 15. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
    Shaarawy M, Darwish NA, Abdel-Aziz O.
    J Soc Gynecol Investig; 1996 Jun; 3(1):39-46. PubMed ID: 8796806
    [Abstract] [Full Text] [Related]

  • 16. Serum SP1, hPL and beta-hCG levels in trophoblastic diseases.
    Zhang WY, Yen GL.
    Chin Med J (Engl); 1991 Dec; 104(12):995-8. PubMed ID: 1723674
    [Abstract] [Full Text] [Related]

  • 17. Persistent low-level "real" human chorionic gonadotropin: a clinical challenge and a therapeutic dilemma.
    Kohorn EI.
    Gynecol Oncol; 2002 May; 85(2):315-20. PubMed ID: 11972394
    [Abstract] [Full Text] [Related]

  • 18. Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study.
    Kim BW, Cho H, Kim H, Nam EJ, Kim SW, Kim S, Kim YT, Kim JH.
    Eur J Obstet Gynecol Reprod Biol; 2012 Jan; 160(1):100-5. PubMed ID: 22055909
    [Abstract] [Full Text] [Related]

  • 19. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy.
    Wolfberg AJ, Berkowitz RS, Goldstein DP, Feltmate C, Lieberman E.
    Obstet Gynecol; 2005 Sep; 106(3):548-52. PubMed ID: 16135585
    [Abstract] [Full Text] [Related]

  • 20. Serum progesterone monitoring in post-molar surveillance.
    Vasilev SA, Schlaerth JB, Ahn C, Sauer MV.
    Gynecol Oncol; 1994 Sep; 54(3):288-91. PubMed ID: 7522199
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.